Catalan Institute of Oncology, Badalona, Spain.
Cancer Discov. 2012 Sep;2(9):769-71. doi: 10.1158/2159-8290.CD-12-0346.
Overexpression of PARP1 and enhancer of zeste homolog 2 (EZH2) has been identified in an integrated analysis of multiple proteins involved in intracellular signaling pathways in small cell lung cancer (SCLC) cell lines. The knockdown of PARP1 and EZH2 abrogated SCLC growth. These findings provide the basis for novel predictive markers and new treatment strategies in SCLC, for which there is now a paucity of available therapies.
在对小细胞肺癌 (SCLC) 细胞系中涉及细胞内信号通路的多种蛋白质进行的综合分析中，鉴定出 PARP1 和增强子的锌指蛋白 2 (EZH2) 的过表达。PARP1 和 EZH2 的敲低可阻断 SCLC 的生长。这些发现为 SCLC 提供了新的预测标志物和新的治疗策略的基础，而目前针对 SCLC 的治疗方法却很少。
